Lecigon,

Entacapone, the active ingredient in Lecigon, is a dopamine precursor combination (MAO‑B inhibitor + DOPA decarboxylase inhibitor) presented as an oral tablet for intestinal use. It is used to treat Parkinson's disease by enhancing and prolonging the effect of levodopa in adult patients.

GNH USA supplies Lecigon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lecigon is a combination therapy that targets motor symptoms in Parkinson's disease and related levodopa‑induced fluctuations.

- Parkinson's disease: improves overall motor control and reduces OFF periods. - Levodopa‑induced wearing‑off: prolongs levodopa plasma half‑life, decreasing dosing frequency. - Advanced Parkinson's disease with motor fluctuations: helps maintain more consistent dopaminergic stimulation.

Lecigon may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dyskinesia: involuntary movements, especially at higher levodopa levels. - Dizziness: may occur when standing quickly. - Constipation: reduced bowel motility. - Dry mouth: decreased salivation. - Headache: transient cranial discomfort.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure drop requiring medical attention. - Neuroleptic malignant syndrome: rare but life‑threatening reaction. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Agranulocytosis: dangerously low white‑blood‑cell count. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Psychiatric disturbances: hallucinations or confusion, especially in the elderly.

Before initiating Lecigon, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Renal impairment: assess kidney function and adjust monitoring as needed. - Hepatic impairment: use with caution; monitor liver enzymes regularly. - Cardiovascular disease: observe blood pressure for orthostatic changes. - Psychiatric history: watch for hallucinations, confusion, or mood swings. - Concomitant MAO‑B inhibitors: avoid combined use to prevent excessive dopaminergic activity. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lecigon interacts with several drug classes; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Certain antihypertensives (e.g., alpha‑blockers): may cause severe hypotension. - Antipsychotics with strong dopamine blockade: can diminish therapeutic effect.

Moderate Interactions (Monitor Closely): - SSRIs and SNRIs: may increase risk of serotonin syndrome. - Other dopaminergic agents (e.g., pramipexole): may enhance dopaminergic side effects. - Iron or calcium supplements: can reduce levodopa absorption; separate dosing by at least 2 hours.